ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

Group 1 - ADC Therapeutics reported a quarterly loss of $0.42 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.36, representing an earnings surprise of -16.67% [1] - The company posted revenues of $18.46 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 1.56$14.49 million year-over-year [2] - The stock has increased approximately 92.8% since the beginning of the year, outperforming the S&P 500's gain of 24.3% [3] Group 2 - The earnings outlook for ADC Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.35 on revenues of$19.76 million, and -$1.72 on revenues of$74 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which ADC Therapeutics belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]